Yumanity Therapeutics (FRA:8IY) Accounts Payable & Accrued Expense : €2.70 Mil (As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics Accounts Payable & Accrued Expense?

Yumanity Therapeutics's quarterly accounts payable & accrued expense declined from Mar. 2022 (€3.45 Mil) to Jun. 2022 (€3.12 Mil) and declined from Jun. 2022 (€3.12 Mil) to Sep. 2022 (€2.70 Mil).

Yumanity Therapeutics's annual accounts payable & accrued expense increased from Dec. 2019 (€2.71 Mil) to Dec. 2020 (€8.99 Mil) but then declined from Dec. 2020 (€8.99 Mil) to Dec. 2021 (€4.36 Mil).

Yumanity Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Yumanity Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yumanity Therapeutics Accounts Payable & Accrued Expense Chart

Yumanity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Accounts Payable & Accrued Expense

2.71

8.99

4.36

Yumanity Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial							4.23	4.36	3.45	3.12	2.70

Yumanity Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Yumanity Therapeutics (FRA:8IY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (FRA:8IY) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

40 Guest Street, Suite 4410, Boston, MA, USA, 02135

Website

https://www.yumanity.com

Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Yumanity Therapeutics (FRA:8IY) Headlines

No Headlines